AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.11
+0.09 (1.79%)
At close: Jul 25, 2025, 4:00 PM
5.12
+0.01 (0.20%)
After-hours: Jul 25, 2025, 7:59 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 5 analysts that cover AbCellera Biologics stock have a consensus rating of "Strong Buy" and an average price target of $8.75, which forecasts a 71.23% increase in the stock price over the next year. The lowest target is $5 and the highest is $10.
Price Target: $8.75 (+71.23%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +95.69% | Jul 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | -2.15% | Jul 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +95.69% | May 16, 2025 |
| Keybanc | Keybanc | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | -2.15% | Apr 16, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 3, 2025 |
Financial Forecast
Revenue This Year
21.57M
from 28.83M
Decreased by -25.19%
Revenue Next Year
36.91M
from 21.57M
Increased by 71.11%
EPS This Year
-0.68
from -0.55
EPS Next Year
-0.59
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.5M | 60.9M | 72.5M | ||
| Avg | 21.6M | 36.9M | 46.9M | ||
| Low | 15.7M | 28.5M | 30.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.6% | 182.3% | 96.3% | ||
| Avg | -25.2% | 71.1% | 27.1% | ||
| Low | -45.5% | 31.9% | -18.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.61 | -0.29 | -0.59 | ||
| Avg | -0.68 | -0.59 | -0.72 | ||
| Low | -0.74 | -0.79 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.